A large clinical trial found that a daily semaglutide pill produced significant weight loss and health benefits comparable to injectable versions, setting the stage for possible FDA approval later this year. A daily pill containing Read More
Tags :trial
Education, Research & Positions
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial Summary A phase 1/2 clinical trial investigated the safety and efficacy of GD2-targeting CAR T cells in children and young adults with Read More
Education, Research & Positions
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary A correction was issued regarding the phase 2 SWOG S1512 trial, which investigated anti-PD-1 therapy (pembrolizumab) for unresectable desmoplastic melanoma. The correction Read More
Education, Research & Positions
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/phase
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/phase 2 trial Summary This Phase 1/Phase 2 trial investigates the safety and efficacy of GD2-targeted CAR T cell therapy in patients with high-risk neuroblastoma, a Read More
Education, Research & Positions
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer:
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial Summary A phase 2 trial investigated sacituzumab tirumotecan combined with tagitanlimab as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study Read More
Education, Research & Positions
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study Read More
Education, Research & Positions
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer:
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results Summary The AMPLIFY-201 phase 1 trial evaluated a novel lymph node-targeted vaccine targeting the mKRAS mutation in patients with pancreatic and Read More
Education, Research & Positions
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial Summary The KEYNOTE-426 trial investigated pembrolizumab plus axitinib versus sunitinib for advanced clear Read More
Education, Research & Positions
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma:
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B Summary The DisTinGuish trial Part B investigated the combination of DKN-01, a DKK1 inhibitor, and tislelizumab, an anti-PD-1 antibody, as Read More
Education, Research & Positions
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial Summary This phase 1 clinical trial investigated the safety and efficacy of intracerebroventricular (ICV) administration of bivalent CAR T cells Read More
Site Logo
Powered by AI
New Journal Citation Reports (JCR) 2025
All-Time Views
1 Million+ Views and Counting..!
Follow me on Linkedin for Latest Jobs and Scholarships
Subscribe Youtube
Celebrating 7 Years
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
Site Trust Score
Google Safe
